Entropy Technologies LP Purchases New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Entropy Technologies LP acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 7,604 shares of the biotechnology company's stock, valued at approximately $500,000.

A number of other institutional investors also recently added to or reduced their stakes in BMRN. nVerses Capital LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,000. TD Private Client Wealth LLC boosted its stake in shares of BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares in the last quarter. Meeder Asset Management Inc. boosted its stake in shares of BioMarin Pharmaceutical by 920.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 663 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of BioMarin Pharmaceutical by 56.1% during the 3rd quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 281 shares in the last quarter. Finally, True Wealth Design LLC boosted its stake in shares of BioMarin Pharmaceutical by 13,400.0% during the 3rd quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 804 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BMRN shares. Evercore ISI decreased their price target on BioMarin Pharmaceutical from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 30th. William Blair lowered BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, October 30th. Robert W. Baird reduced their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a research note on Wednesday, October 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $80.00 target price on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 30th. Finally, UBS Group upped their target price on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of "Moderate Buy" and a consensus price target of $94.20.

BioMarin Pharmaceutical Trading Up 0.7 %

Shares of BMRN stock traded up $0.43 on Friday, reaching $64.85. 1,048,855 shares of the stock were exchanged, compared to its average volume of 1,674,690. The stock has a market cap of $12.36 billion, a P/E ratio of 38.83, a price-to-earnings-growth ratio of 0.57 and a beta of 0.28. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average of $64.86 and a two-hundred day moving average of $71.47. BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.